Cryo-Cell International Inc(CCEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 3:35 PM ET (Korea 10/30 04:35)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.24 | Insider Own | 47.86% | Shs Outstand | 8.1M | Perf Week | 15.48% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.2M | Perf Month | 23.45% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 13.72% | Short Float | 0.17% | Perf Quarter | 51.61% |
| Income | -0.00B | P/S | 1.34 | EPS this Y | - | Inst Trans | 1.88% | Short Ratio | 0.29 | Perf Half Y | 51.61% |
| Sales | 0.03B | P/B | - | EPS next 5Y | - | ROA | -3.1% | Short Interest | 0.01M | Perf YTD | 50.73% |
| Book/sh | -2.03 | P/C | 9.88 | EPS past 3/5Y | - | ROE | - | 52W High | -3.08% ($5.35) | Perf Year | 17.81% |
| Cash/sh | 0.52 | P/FCF | 8.99 | Sales past 3/5Y | 1.33% 0.27% | ROIC | - | 52W Low | 90.62% ($2.72) | Perf 3Y | 8.25% |
| Dividend Est. | - | EV/EBITDA | 30.13 | EPS Y/Y TTM | -314.41% | Gross Margin | 76.17% | Volatility(W/M) | 8.43% 10.2% | Perf 5Y | -52.94% |
| Dividend TTM | - | EV/Sales | 1.49 | Sales Y/Y TTM | -1.96% | Oper. Margin | 0.61% | ATR (14) | 0.42 | Perf 10Y | 43.08% |
| Dividend Ex-Date | 2025/5/21 | Quick Ratio | 0.82 | EPS Q/Q | 69.72% | Profit Margin | -6.25% | RSI (14) | 63.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.86 | Sales Q/Q | -0.02% | SMA20 | 17.38% ($4.41) | Beta | 0.49 | Target Price | $8.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/10/9 | SMA50 | 20.96% ($4.28) | Rel Volume | 0.33 | Prev Close | $5.12 |
| Employees | 76 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 41.3% ($3.67) | Avg Volume(3M) | 0.02M | Price | $5.18 |
| IPO | 1994/4/4 | Option/Short | No/Yes | Trades | 115 | Volume | 8,072 | Change | 1.17% |
🧬 Cryo-Cell International is the world's first private cord blood bank—a U.S. healthcare company that provides family-based long-term storage of stem cells collected from newborns' umbilical cord blood and cord tissue. It is a small-cap company listed on Nasdaq and generates stable recurring revenue through a combination of new-contract fees and annual storage fees. Since its founding in 1989, it has been a traditional niche company that has consistently remained profitable.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded less than usual. That is 33% of its average volume.
CCEL keeps an operating profit but posts a net loss
Of every $100 in sales, $0.61 is kept as operating profit.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $134. Peers typically go for $95. Compared with its own 5-year average, it is 12% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -52.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 13.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #42 of 48 in the industry
Based on market cap of $42M.
BTMD#41 biote Corp $42M PER 9.7 CCEL#42 Cryo-Cell International Inc $42M PER - 
BMGL#43 Basel Medical Group Ltd $36M PER - 
PIII#44 P3 Health Partners Inc $31M PER - 
DCGO#45 DocGo Inc $27M PER - 
FAQ
What kind of company is CCEL?
CCEL belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of CCEL?
The market cap of CCEL is approximately $42M, ranking 4,946 within its sector.
What is the 52-week high and low for CCEL?
CCEL has recorded a 52-week high of $5.35 and a low of $2.72.
